Insider Trading April 1, 2026

Lument Finance Trust Director Adds 5,000 Shares as Stock Nears Year Low

William A. Houlihan increases his stake while the company reports a disappointing quarter and trades at depressed multiples

By Maya Rios LFT
Lument Finance Trust Director Adds 5,000 Shares as Stock Nears Year Low
LFT

William A. Houlihan, a director at Lument Finance Trust, purchased 5,000 shares on March 27, 2026, bringing his direct holdings to 260,732 shares. The trade occurred as the stock traded near $1.26 and followed a weak fourth-quarter performance that missed consensus on both EPS and revenue. The company offers a high dividend yield and a low price-to-book multiple amid a significant six-month decline in its share price.

Key Points

  • A company director purchased 5,000 shares at $1.30 on March 27, 2026, increasing direct holdings to 260,732 shares - impacts investor perception and insider ownership metrics.
  • Lument Finance Trust reported a fourth-quarter 2025 EPS of -$0.17, missing the $0.08 forecast by 312.5%, and revenue of $4.96 million, a 26.19% shortfall versus expectations - these results are material to earnings and revenue assessments in the financials sector.
  • The stock is trading near $1.26, close to a 52-week low of $1.18, has fallen 33% over six months, yields 12.7%, and trades at a price-to-book of 0.41 - relevant datapoints for equity and income-focused investors in the capital markets.

William A. Houlihan, a member of Lument Finance Trust's board, bought 5,000 shares of the company's common stock on March 27, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The purchase was executed at $1.30 per share, for a total outlay of $6,500. After the transaction, Houlihan directly holds 260,732 shares of the company.

The insider purchase comes as the stock is trading around $1.26 and sits close to its 52-week low of $1.18. Over the past six months the shares have fallen about 33%, leaving the market price at a materially lower level than earlier in the period.

Market metrics cited alongside the filing show the company yields a significant dividend, quoted at 12.7%, and trades at a price-to-book ratio of 0.41. An independent analysis referenced in the regulatory filing indicates the shares appear overvalued relative to the analysis's assessed fair value. Those figures highlight a contrast between a high income yield and apparent valuation concerns at current market prices.


Financial results announced for the fourth quarter of 2025 provide additional context for the recent price action. Lument Finance Trust reported an earnings per share (EPS) of -$0.17 for the quarter, missing the consensus forecast of $0.08. That shortfall represents a negative surprise of 312.5% versus expectations. On the top line, revenue for the quarter was $4.96 million, below the expected $6.72 million, a shortfall of 26.19%.

These results are notable developments in the company's recent performance and are likely to influence how investors and analysts evaluate the firm's near-term prospects. The combination of a steep EPS miss and a measurable revenue decline are listed among the principal concerns raised by the latest disclosure.


Houlihan's acquisition of 5,000 shares is recorded as a direct purchase and increases his ownership stake modestly. The filing does not provide further commentary from the director or the company on the motivation for the purchase or any change in strategy.

Investors assessing Lument Finance Trust will weigh the insider purchase against the recent financial results, the company's dividend yield and its low price-to-book multiple, as well as the recent 33% drop in the share price over six months. The filing and the quarter-end disclosures together form the primary public data points available in the latest reporting cycle.


Market context

  • The director purchase was executed at $1.30 per share for a total of $6,500.
  • Post-transaction direct holdings for the director stand at 260,732 shares.
  • Recent quarter results showed an EPS of -$0.17 versus an expected $0.08 and revenue of $4.96 million versus an expected $6.72 million.

All figures above are reported in the company's regulatory filings and the most recent quarterly disclosures.

Risks

  • Earnings and revenue surprises: The company recorded a large EPS miss and a notable revenue shortfall for Q4 2025, raising near-term performance uncertainty for shareholders and analysts in the financial sector.
  • Valuation and price volatility: The share price has declined 33% over six months and is trading near its 52-week low, creating downside risk for equity investors and placing pressure on dividend sustainability assessments.
  • Limited disclosure on insider intent: The Form 4 records the purchase but does not include an explanation for the transaction, leaving questions about the strategic rationale and its implications for corporate outlook.

More from Insider Trading

Saba Capital Trims Stake in BlackRock ESG Trust, Selling 262,345 ECAT Shares Apr 1, 2026 Oil States director sells $493k in stake as company posts mixed quarterly results and leadership change Apr 1, 2026 Harvard Bioscience CFO Buys $25,000 of Stock as Company Outlines 2026 Plan Apr 1, 2026 Japan Post Reduces Aflac Holding with $1.59 Million Sale Apr 1, 2026 Tonix CEO Makes Notable Purchase as Company Advances Clinical Programs Apr 1, 2026